# US Patient Derived Xenograft Model Market > US Patient-Derived Xenograft Model Market Research Report: Size, Share, Trend Analysis By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer), By Model Type (Mice, Rats) and By End-User (Pharmaceutical, Biopharmaceutical Companies, Academic & Research Institutes, CROs, CDMOs) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 13.3% - **2024:** $ 88.51 Million - **2025:** $ 100.28 Million - **2035:** $ 349.63 Million - **Key Players:** Charles River Laboratories (US), Crown Bioscience (US), Horizon Discovery (GB), OncoOne (US), The Jackson Laboratory (US), XenoTech (US), Celerion (US), CureMetrix (US) **Report ID:** MRFR/HC/15216-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-patient-derived-xenograft-model-market-16744 --- ## Market Summary ## **US Patient-Derived Xenograft Model Market Overview** As per MRFR analysis, the US Patient-Derived Xenograft Model Market Size was estimated at 79.08 (USD Million) in 2023. The US Patient-Derived Xenograft Model Market Industry is expected to grow from 89.6 (USD Million) in 2024 to 348.96 (USD Million) by 2035. The US Patient-Derived Xenograft Model Market CAGR (growth rate) is expected to be around 13.156% during the forecast period (2025 - 2035). ### **Key US Patient-Derived Xenograft Model Market Trends Highlighted** The US Patient-Derived Xenograft (PDX) Model market is witnessing significant growth driven by several key market drivers. Increased investment in personalized medicine is one of the primary factors, as researchers and biotechnology firms look to develop tailored therapies that cater to individual patient needs. Advances in technology, particularly with regard to genomic sequencing and biobanking, have enabled the successful establishment of PDX models, allowing for better understanding of tumor biology and drug responses. Moreover, there is a heightened focus on cancer research within federal agencies and significant funding from initiatives designed to enhance cancer research capabilities in the US, contributing to the demand for PDX models. Opportunities to be explored in this market include collaborations between academic institutions and private sector companies. Such partnerships can lead to significant advancements in understanding tumor heterogeneity and improving treatment methodologies. Furthermore, there is a growing trend of utilizing PDX models in drug efficacy testing, which opens up avenues for pharmaceutical companies to refine their pipelines and enhance drug development processes. The ability to closely mimic human tumors makes PDX models invaluable in the clinical setting, further driving their adoption. Trends in recent times also indicate a shift towards integrating PDX models with artificial intelligence and machine learning to predict treatment outcomes more accurately. This complements the traditional experimental approaches, allowing researchers to derive more robust insights from PDX studies. As more users begin to realize the limitations of traditional cancer models, the shift towards using PDX models is poised to accelerate, creating new pathways for research and development in oncology within the US. Overall, the dynamic evolution of the PDX model market underscores its essential role in contemporary cancer research and personalized therapeutics in the US. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Patient-Derived Xenograft Model Market Drivers** ### **Rising Incidence of Cancer in the United States** The US [Patient-Derived Xenograft Model Market](../../../reports/patient-derived-xenograft-model-market-12128) Industry is significantly driven by the increasing incidence of cancer across the nation. The American Cancer Society reports that in 2023, an estimated 1.9 million new cancer cases are expected to be diagnosed, with cancer remaining a leading cause of death in the United States. With a growing patient population, the demand for effective research tools, such as patient-derived xenograft models, is expanding. These models are essential for personalized medicine in oncology, helping to identify the most effective treatments for individual patients. The National Institutes of Health has emphasized the importance of this research in developing targeted therapies, which further validates the urgency for innovations in preclinical cancer research. ### **Advancements in Research and Development** Ongoing advancements in Research and Development within the biomedical sector are empowering the US Patient-Derived Xenograft Model Market Industry. The National Institutes of Health has reported a 10% annual increase in funding for cancer research, now exceeding 6 billion USD annually. This funding boosts the development of innovative xenograft models, which provide a more accurate representation of human tumors, thus enhancing the reliability of preclinical research. This rising investment in biomedical innovation is crucial, as it influences competitors and research institutions to adopt advanced models for drug efficacy testing and biological studies, ultimately supporting faster breakthroughs in cancer treatment. ### **Increased Collaborations between Academia and Industry** There has been a noticeable rise in collaborations between academic institutions and industry players to leverage patient-derived xenograft models effectively in the United States. Reports indicate a 15% increase in partnership agreements in the last three years, with major organizations such as the American Association for Cancer Research facilitating these connections. Collaboration accelerates the translation of laboratory discoveries into clinical applications, boosting the availability of patient-derived xenograft models in pharmaceutical development pipelines. As more research laboratories partner with established biopharmaceutical companies, the integration of these models into drug testing phases is expected to rise, enhancing the overall market landscape. ### **Emphasis on Personalized Medicine** The shifting healthcare paradigm toward personalized medicine is a key driver of growth in the US Patient-Derived Xenograft Model Market Industry. According to the Food and Drug Administration, more than 60% of new drugs approved in recent years have been developed using personalized approaches, and this trend is expected to continue. Patient-derived xenograft models play a crucial role in understanding individual patient responses to different therapies, thus supporting the goal of personalized treatments. The increase in tailored therapeutics paves the way for the higher adoption of these models in clinical research, ultimately enhancing their relevance and demand in the market. ## **US Patient-Derived Xenograft Model Market Segment Insights** ### **Patient-Derived Xenograft Model Market Tumor Type Insights** The US Patient-Derived Xenograft Model Market, particularly in the context of Tumor Type, presents a diverse landscape characterized by various cancer types, each holding significant relevance in research and therapeutic applications. Lung cancer remains a prominent focus within this market segment due to its high incidence and mortality rates in the United States, driving demand for innovative treatment models to better understand tumorigenesis and test new drug candidates. Pancreatic cancer, while less common, has garnered increasing attention due to its aggressive nature and poor prognoses, necessitating advanced research models that can mimic patient responses. Prostate cancer, being one of the most frequently diagnosed cancers among men, influences the US Patient-Derived Xenograft Model Market by creating a need for reliable preclinical models that assist in the development of targeted therapies and understand biochemical pathways. Breast cancer, meanwhile, represents a large patient population and benefits from extensive research efforts aimed at personalizing treatment approaches, thus contributing to the overall demand for patient-derived xenograft models. Other cancer types also play a crucial role in this segmented market, as they encompass diverse pathologies requiring unique models to explore effective treatment strategies. The advent of personalized medicine and increasing funding directed towards cancer research serve as growth drivers, while challenges such as model standardization and high operational costs may inhibit broader adoption. Collectively, the Tumor Type segment within the US Patient-Derived Xenograft Model Market highlights the critical need for specialized research tools that can deal with the complexities of cancer biology and improve therapeutic outcomes. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Patient-Derived Xenograft Model Market Model Type Insights** The US Patient-Derived Xenograft Model Market is characterized by distinct models, primarily including Mice and Rats, both of which play crucial roles in preclinical research, specifically in cancer therapy and drug development. Mice have been widely recognized for their genetic similarity to humans, allowing researchers to study human diseases effectively. This model type is preferred for its ability to facilitate high-throughput screening and analyze therapeutic responses. Rats, on the other hand, offer advantages in pharmacokinetics and behavioral studies due to their larger size, which makes them suitable for some surgical interventions and monitoring complex behaviors. The combination of these model types in the US market exemplifies the trend towards personalized medicine, with increasing demand for advanced models that assist in tailored treatment approaches. The robust growth of Research and Development efforts in biotechnology and pharmaceutical sectors drives the need for effective xenograft models, as they provide critical insights into tumor biology and treatment efficacy. Both Mice and Rats are essential for addressing the challenges posed by human variability, maximizing the success rates in translational research, and ultimately enhancing patient outcomes in oncology treatments. ### **Patient-Derived Xenograft Model Market End-User Insights** The End-User segment of the US Patient-Derived Xenograft Model Market encompasses a diverse range of applications across various industries. Pharmaceutical and Biopharmaceutical Companies are key drivers in utilizing these models for drug discovery and development, enabling more targeted therapies and reducing the time to market. Academic and Research Institutes leverage patient-derived xenografts for translational research, contributing significantly to advancements in personalized medicine. Contract Research Organizations (CROs) play a crucial role in facilitating studies using these models, catering to the growing demand for outsourced research services. Furthermore, Contract Development and Manufacturing Organizations (CDMOs) utilize these models to enhance their drug development processes, thus supporting biopharmaceutical product pipelines. The increasing prevalence of complex diseases and the growing focus on tailored therapies are among the main growth drivers in this segment. Challenges such as regulatory compliance and model standardization remain, yet the opportunities for innovation and collaboration within this sector continue to expand as the demand for effective and patient-centered medical solutions rises. In this competitive landscape, each End-User type navigates its unique challenges and advantages, collectively shaping the trajectory of the US Patient-Derived Xenograft Model Market. ## **US Patient-Derived Xenograft Model Market Key Players and Competitive Insights** The US Patient-Derived Xenograft Model Market has emerged as a crucial component in the landscape of biomedical research and drug development, focusing on providing models that accurately replicate human cancers for preclinical studies. This market is characterized by a complex interplay of biotechnology firms, research institutions, and pharmaceutical companies that continuously innovate to improve PDX models. The competitive insights in this landscape are shaped by factors such as technological advancements, regulatory frameworks, and the relentless pursuit of personalized medicine. Companies are increasingly leveraging collaborations and strategic alliances to enhance their capabilities and expand their market reach, leading to a dynamic environment where competition drives better patient outcomes and accelerates the path to novel therapies. The Jackson Laboratory stands out in the US Patient-Derived Xenograft Model Market due to its robust commitment to genetics and cancer research. With a rich history of facilitating innovative experiments, The Jackson Laboratory is recognized for its unparalleled quality in developing and providing patient-derived xenograft models that serve as reliable platforms for drug testing and therapeutic validation. Their strengths lie in their expert workforce, comprehensive resources, and substantial investment in research and development, which collectively empower them to deliver advanced models tailored to meet specific research needs. The Jackson Laboratory's established reputation and academic partnerships further bolster its presence in the market, providing researchers with valuable resources and support, thereby enhancing its competitive edge. Genentech holds a formidable position within the US Patient-Derived Xenograft Model Market, leveraging its extensive expertise in biotechnology to create therapies that address unmet medical needs. The company is known for its innovative solutions in cancer treatment, drawing upon its robust pipeline that includes therapies extensively validated through PDX models. Genentech’s strengths include a strong focus on research collaborations with academic institutions and biopharmaceutical entities, which facilitates access to the latest findings and technologies. Its strategic approach to mergers and acquisitions has further solidified its market presence, allowing for expanded capabilities and diversification of product offerings. This proactive stance not only enhances Genentech's portfolio but also drives advancements in personalized medicine, solidifying its role as a leader in the US Patient-Derived Xenograft Model Market. ### **Key Companies in the US Patient-Derived Xenograft Model Market Include** ## **US Patient-Derived Xenograft Model Market Industry Developments** The US Patient-Derived Xenograft Model Market has seen significant developments recently, particularly in the context of advancements in cancer research. The Jackson Laboratory continues to drive innovation with their expanding portfolio of mouse models tailored for precision medicine. Inovia Pharmaceuticals and Bristol Myers Squibb are leveraging patient-derived xenografts to enhance their drug development pipelines, showing a growing recognition of these models in oncology. In September 2023, Crown Bioscience announced an expansion of their services, significantly increasing capabilities in PDX models for a variety of cancer types. Mergers and acquisitions have also been a notable trend, with Inovio Pharmaceuticals acquiring a smaller biotech firm to bolster their Research and Development in this area, announced in August 2023. This trend is complemented by AstraZeneca and Genentech increasing investments in partnerships for improved access to patient-derived models, reflecting a robust growth trajectory in the market valuation of these companies. The focus on patient-centered approaches in drug development and the utilization of cutting-edge technologies are shaping the landscape of the US Patient-Derived Xenograft Model Market, marked by key happenings over the last two to three years that demonstrate significant market potential. ## **US Patient-Derived Xenograft Model Market Segmentation Insights** ### **Patient-Derived Xenograft Model Market Tumor Type Outlook** ### **Patient-Derived Xenograft Model Market Model Type Outlook** ### **Patient-Derived Xenograft Model Market End-User Outlook** ## Market Drivers ### Rising Incidence of Rare Cancers The patient derived-xenograft-model market is also influenced by the rising incidence of rare cancers, which often lack effective treatment options. As the understanding of cancer biology deepens, there is a growing recognition of the need for tailored therapeutic approaches. Patient derived-xenograft models provide a unique opportunity to study these rare cancers in a preclinical setting, facilitating the development of targeted therapies. In 2025, it is projected that approximately 200,000 new cases of rare cancers will be diagnosed in the US, underscoring the urgency for innovative research models. This increasing incidence is likely to drive demand for patient derived-xenograft models, as researchers seek to explore novel treatment avenues. ### Increasing Investment in Oncology Research The patient derived-xenograft-model market is experiencing a surge in investment, particularly in oncology research. As the prevalence of cancer continues to rise, funding from both public and private sectors is directed towards innovative research methodologies. In 2025, the National Cancer Institute allocated approximately $6.5 billion to cancer research initiatives, which includes the development of patient derived-xenograft models. This influx of capital is likely to enhance the capabilities of researchers to develop more effective therapies, thereby driving the demand for these models in preclinical testing. The focus on personalized treatment options further emphasizes the need for accurate models that can mimic human tumor biology, making this investment a critical driver in the patient derived-xenograft-model market. ### Growing Focus on Drug Development Efficiency The patient derived-xenograft-model market is being propelled by an increasing emphasis on the efficiency of drug development processes. Pharmaceutical companies are under pressure to reduce the time and costs associated with bringing new drugs to market. Patient derived-xenograft models offer a more predictive platform for evaluating drug efficacy and safety compared to traditional methods. In 2025, it is estimated that the average cost of developing a new drug exceeds $2.6 billion, highlighting the need for more effective preclinical models. By utilizing patient derived-xenograft models, companies can potentially streamline their research and development phases, thereby enhancing their competitive edge in the market. This focus on efficiency is a significant driver for the patient derived-xenograft-model market. ### Technological Advancements in Model Development Technological innovations are playing a pivotal role in the evolution of the patient derived-xenograft-model market. Recent advancements in genetic engineering, imaging techniques, and biomanufacturing processes have significantly improved the efficiency and accuracy of xenograft models. For instance, the integration of CRISPR technology allows for precise genetic modifications, enabling researchers to create models that closely resemble human tumors. This technological progress not only enhances the reliability of preclinical studies but also reduces the time and cost associated with model development. As a result, the patient derived-xenograft-model market is likely to expand, driven by the demand for more sophisticated and representative models in drug discovery and development. ### Enhanced Collaboration Between Academia and Industry The patient derived-xenograft-model market is benefiting from enhanced collaboration between academic institutions and the pharmaceutical industry. Such partnerships are fostering innovation and accelerating the translation of research findings into clinical applications. In 2025, numerous collaborative initiatives are underway, focusing on the development of patient derived-xenograft models for various cancer types. These collaborations often involve sharing resources, expertise, and data, which can lead to more robust model development and validation. As the synergy between academia and industry strengthens, the patient derived-xenograft-model market is likely to see increased growth, driven by the collective efforts to advance cancer research and treatment. ## Future Outlook The [Patient Derived Xenograft Model Market](https://www.marketresearchfuture.com/reports/patient-derived-xenograft-model-market-12128) is projected to grow at a 13.3% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increased R&D investments, and rising demand for effective cancer therapies. **New opportunities:** - Development of advanced bioreactors for enhanced tumor growth Partnerships with biotech firms for innovative drug testing Expansion into emerging markets with tailored solutions By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in cancer research. ## Segment Insights ### By Tumor Type: Lung Cancer (Largest) vs. Breast Cancer (Fastest-Growing) In the US patient derived-xenograft-model market, Lung Cancer has emerged as the largest segment, commanding a significant share due to its high incidence and mortality rates. It is closely followed by Prostate Cancer and Breast Cancer, which also contribute considerably to the market. Other cancers collectively present a smaller yet relevant portion of the segment, indicating a diverse landscape of tumor types being researched and treated. The growth trends in this segment are notably driven by advancements in personalized medicine and increasing investments in cancer research. Breast Cancer, in particular, is recognized as the fastest-growing segment, reflecting heightened awareness and improved screening practices. Innovations in xenograft models increase the efficacy of treatment options tailored for different tumor types, while growing support for clinical trials catalyzes further development in the segment. Lung Cancer (Dominant) vs. Breast Cancer (Emerging) Lung Cancer represents a dominant force in the US patient derived-xenograft-model market, primarily due to its prevalence and the ongoing need for effective therapies. Preclinical models are essential for understanding the biological processes of this type of cancer, thus facilitating the development of targeted therapies. Conversely, Breast Cancer is emerging rapidly in this market, driven by increased research funding and a focus on developing innovative treatment modalities. Models for Breast Cancer are gaining traction, enabled by robust clinical data supporting personalized approaches and enhanced efficacy evaluations in drug development. Both segments are crucial for advancing therapeutic options but vary significantly in their maturity and research focus. ### By Model Type: Mice (Largest) vs. Rats (Fastest-Growing) In the US patient derived-xenograft-model market, the model type segment is predominantly led by the use of mice, which holds the largest share. Mice have established themselves as the preferred choice due to their favorable genetic traits, shorter life cycles, and the relative ease of manipulation for various research purposes. This widespread adoption has solidified their position, making them a vital asset in preclinical studies. On the other hand, rats are emerging as the fastest-growing segment within the model type category. Their anatomical and physiological similarities to humans allow for a more accurate representation of human disease, driving increased adoption in research. Furthermore, advancements in genetic engineering and rat breeding techniques have contributed to their rising popularity, making them an attractive alternative to traditional models. Mice (Dominant) vs. Rats (Emerging) Mice are the dominant model type in the patient derived-xenograft-model market, valued for their high reproduction rates and extensive genetic modification capability. These traits not only enhance the reliability of preclinical trials but also facilitate the analysis of various disease states. The growing emphasis on personalized medicine further supports the extensive use of mice as they can be customized to closely mimic human pathology. Conversely, rats are becoming an emerging choice due to their size and behavioral characteristics that resemble those of humans more closely than mice. This allows researchers to conduct more thorough investigations into pharmacokinetics and toxicity assessments. As these animals are more aligned with human responses, they are increasingly recognized in developing and validating potential therapeutic interventions. ### By End-user: Pharmaceutical and Biopharmaceutical Companies (Largest) vs. Academic & Research Institutes (Fastest-Growing) The market share distribution among the segment values reveals that Pharmaceutical and Biopharmaceutical Companies dominate the US patient derived-xenograft-model market, holding a significant portion due to their extensive investments in R&D and therapeutic innovations. Academic & Research Institutes follow, increasingly contributing to market growth by harnessing patient-derived models for translational research and drug development, which enhances their role in the overall ecosystem. In terms of growth trends, Academic & Research Institutes are emerging rapidly as they focus on innovative approaches to personalize medicine. The demand for advanced preclinical models, coupled with funding towards cancer biology and personalized treatments, is driving their expansion. Conversely, Pharmaceutical and Biopharmaceutical Companies are enhancing their capabilities through partnerships with CROs and CDMOs, solidifying their leading position while adapting to the evolving landscape of drug development. Pharmaceutical and Biopharmaceutical Companies (Dominant) vs. Academic & Research Institutes (Emerging) Pharmaceutical and Biopharmaceutical Companies occupy a dominant position within the US patient derived-xenograft-model market, benefiting from high levels of investment and a strong focus on developing targeted therapies. Their robust infrastructure, regulatory expertise, and market access allow them to leverage patient-derived models effectively. On the other hand, Academic & Research Institutes are emerging as pivotal players, capitalizing on novel research and the growing necessity for personalized medicine. Their agility in adapting to scientific advancements and collaboration with industry stakeholders enhances their capabilities in developing innovative therapies. This dynamic environment fosters a collaborative ecosystem that drives forward both segments, highlighting their unique strengths and contributions to advancing medical science. ## Competitive Benchmarking The patient derived-xenograft-model market is characterized by a dynamic competitive landscape, driven by increasing demand for personalized medicine and advancements in oncology research. Key players such as Charles River Laboratories (US), Crown Bioscience (US), and The Jackson Laboratory (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Charles River Laboratories (US) focuses on innovation through the development of advanced xenograft models that cater to specific cancer types, thereby enhancing their research capabilities. Meanwhile, Crown Bioscience (US) emphasizes strategic partnerships with pharmaceutical companies to expand its service offerings and improve drug development processes. The Jackson Laboratory (US) is leveraging its extensive genetic research to create more accurate patient-derived models, which positions it as a leader in precision medicine. Collectively, these strategies contribute to a competitive environment that is increasingly centered around innovation and collaboration.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies is significant, as they drive advancements in technology and research methodologies, thereby shaping the overall market structure. In October Charles River Laboratories (US) announced a collaboration with a leading biotech firm to develop a new line of patient-derived xenograft models tailored for immunotherapy research. This strategic move is likely to enhance their product portfolio and strengthen their position in the rapidly evolving field of cancer treatment. By focusing on immunotherapy, Charles River Laboratories (US) aligns itself with current trends in oncology, potentially increasing its market share. In September Crown Bioscience (US) launched a new platform that integrates artificial intelligence (AI) with patient-derived xenograft models to predict drug responses more accurately. This initiative not only showcases their commitment to innovation but also positions them as a pioneer in utilizing AI for enhancing drug development processes. The integration of AI could significantly improve the efficiency of clinical trials, thereby attracting more partnerships with pharmaceutical companies. In August The Jackson Laboratory (US) expanded its facilities to increase production capacity for its patient-derived models. This expansion is indicative of their commitment to meeting the growing demand for personalized medicine solutions. By enhancing their production capabilities, The Jackson Laboratory (US) is likely to solidify its market position and respond effectively to the increasing needs of researchers and clinicians. As of November current competitive trends in the patient derived-xenograft-model market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly important, as companies seek to leverage each other's strengths to enhance their offerings. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies compete, emphasizing the importance of developing unique solutions that address the specific needs of the market. ## Recent News & Developments The US Patient-Derived Xenograft Model Market has seen significant developments recently, particularly in the context of advancements in cancer research. The Jackson Laboratory continues to drive innovation with their expanding portfolio of mouse models tailored for precision medicine. Inovia Pharmaceuticals and Bristol Myers Squibb are leveraging patient-derived xenografts to enhance their drug development pipelines, showing a growing recognition of these models in oncology. In September 2023, Crown Bioscience announced an expansion of their services, significantly increasing capabilities in PDX models for a variety of cancer types. Mergers and acquisitions have also been a notable trend, with Inovio Pharmaceuticals acquiring a smaller biotech firm to bolster their Research and Development in this area, announced in August 2023. This trend is complemented by AstraZeneca and Genentech increasing investments in partnerships for improved access to patient-derived models, reflecting a robust growth trajectory in the market valuation of these companies. The focus on patient-centered approaches in drug development and the utilization of cutting-edge technologies are shaping the landscape of the US Patient-Derived Xenograft Model Market, marked by key happenings over the last two to three years that demonstrate significant market potential. ## Report Scope | MARKET SIZE 2024 | 88.51(USD Million) | | --- | --- | | MARKET SIZE 2025 | 100.28(USD Million) | | MARKET SIZE 2035 | 349.63(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.3% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Charles River Laboratories (US), Crown Bioscience (US), Horizon Discovery (GB), OncoOne (US), The Jackson Laboratory (US), XenoTech (US), Celerion (US), CureMetrix (US) | | Segments Covered | Tumor Type, Model Type, End-user | | Key Market Opportunities | Advancements in personalized medicine drive demand for innovative patient derived-xenograft-model solutions. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation in patient derived-xenograft-model development and application. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US patient derived-xenograft-model market?** A: The market valuation was $88.51 Million in 2024. **Q: What is the projected market valuation for the US patient derived-xenograft-model market by 2035?** A: The projected valuation for 2035 is $349.63 Million. **Q: What is the expected CAGR for the US patient derived-xenograft-model market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 13.3%. **Q: Which tumor type segment has the highest valuation in the US patient derived-xenograft-model market?** A: The Breast Cancer segment has the highest valuation, ranging from $25.0 Million to $100.0 Million. **Q: What are the key players in the US patient derived-xenograft-model market?** A: Key players include Charles River Laboratories, Crown Bioscience, Horizon Discovery, OncoOne, The Jackson Laboratory, XenoTech, Celerion, and CureMetrix. **Q: Which model type segment contributes the most to the US patient derived-xenograft-model market?** A: The Mice model type contributes the most, with a valuation ranging from $50.0 Million to $200.0 Million. **Q: What is the valuation range for the Pancreatic Cancer segment in the US patient derived-xenograft-model market?** A: The valuation range for the Pancreatic Cancer segment is $15.0 Million to $60.0 Million. **Q: How do academic and research institutes contribute to the US patient derived-xenograft-model market?** A: Academic & Research Institutes contribute a valuation ranging from $30.0 Million to $120.0 Million. **Q: What is the valuation range for the Prostate Cancer segment in the US patient derived-xenograft-model market?** A: The Prostate Cancer segment has a valuation range of $18.0 Million to $70.0 Million. **Q: What is the valuation range for the Other Cancer segment in the US patient derived-xenograft-model market?** A: The Other Cancer segment has a valuation range of $10.51 Million to $39.63 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-patient-derived-xenograft-model-market-16744*